Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNRISE HIV: Eplerenone and Statins for Arterial Inflammation in HIV
NCT07892664Phase 3Not yet recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2027
- Primary completion
- May 2031
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in arteritis and cardiovascular disease (CVD) comparing Eplerenone with Placebo (2 arms). Primary endpoint: Arterial Inflammation at 12 months. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
eplerenone
03
Conditions
arteritiscardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT07892664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07892664.